9 drug(s) with this reaction
6,792 total reports
Cerebrovascular Accident has been reported as an adverse reaction across 9 drug(s) manufactured by Abbvie Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 6,792 adverse event reports mention cerebrovascular accident in connection with Abbvie Inc products.
This page provides a breakdown of which Abbvie Inc drugs are most commonly associated with cerebrovascular accident, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Abbvie Inc drugs have cerebrovascular accident listed in their FDA adverse event reports, sorted by report count:
In addition to cerebrovascular accident, the following adverse reactions have been reported across Abbvie Inc's drug portfolio:
9 drug(s) manufactured by Abbvie Inc have cerebrovascular accident listed in their FDA adverse event reports: LEVOTHYROXINE SODIUM, RISANKIZUMAB-RZAA, FENOFIBRATE, UPADACITINIB, VENETOCLAX, and others.
There are a combined 6,792 reports of cerebrovascular accident across 9 Abbvie Inc drug(s) in the FDA adverse event database.